Cardiac myofiber

Cardiac myofiber is not a single molecular entity but a specialized, striated muscle cell (cardiomyocyte) that forms the primary contractile tissue of the heart[1][5]. Cardiac myofibers are branched, elongated cells, usually containing a single central nucleus, and are connected end-to-end by intercalated discs, enabling synchronized contraction (functional syncytium)[1][5]. Each myofiber contains numerous myofibrils, which are composed of sarcomeres—the fundamental contractile units containing actin, myosin, titin, and other associated proteins[1][3]. Sarcomeres give cardiac muscle its striated appearance under the microscope and are responsible for the sliding filament mechanism of muscle contraction[1][3]. Cardiac myofibers are involuntary and display automaticity due to specialized pacemaker cells, but their contractility can be modulated by the autonomic nervous system, hormones, and drugs[1][5]. These cells have high metabolic demands and are richly supplied with mitochondria to support continuous, fatigue-resistant contraction[1][5]. Diseases affecting cardiac myofibers (e.g., cardiomyopathies, ischemic heart disease) impair the heart’s ability to pump blood, leading to heart failure or lethal arrhythmias[5][7]. While the sarcomeric proteins (e.g., myosin, actin, titin) and ion channels (e.g., sodium, calcium, potassium channels) within myofibers are direct therapeutic targets, "cardiac myofiber" itself is a cellular, not molecular, target—hence, it is not a canonical therapeutic target in the pharmacologic sense[1][5]. The term is sometimes used colloquially to describe the contractile apparatus of the heart but should be specified as "cardiac muscle cell" or "cardiomyocyte" for scientific precision. Drugs "targeting cardiac myofibers" generally act on molecular components within the myofiber (e.g., sarcomeric proteins, ion channels) rather than the myofiber as a whole[5].

Other names

Cardiac muscle fiberCardiomyocyteMyocardial fiberHeart muscle cell

Modulation of cytosolic calcium (e.g., calcium channel blockers reduce calcium influx, digitalis glycosides increase intracellular calcium) Regulation of beta-adrenergic signaling (e.g., beta-blockers antagonize norepinephrine/epinephrine effects) Direct inotropic effects (e.g., digoxin inhibits Na+/K+ ATPase, increasing intracellular calcium)